Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT07421232Phase 2Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2053 in hypercholesterolemia, mixed dyslipidemia, sponsored by CSPC Zhongnuo Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
SYH2053
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07421232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421232.